Sagent Pharmaceuticals (SGNT) Misses Q1 EPS by 16c

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T

6. SPY
7. CVS
8. UNH
9. TMUS
10. VZ

Sagent Pharmaceuticals Reports First Quarter 2016 Financial Results

May 3, 2016 7:30 AM EDT

Â Â Â Â Â Â Company Affirms 2016 Full Year Guidance

Substantial Progress against Long-Term Growth Strategy;

SCHAUMBURG, Ill., May 03, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leading provider of affordable pharmaceuticals to the hospital market, today announced financial results for the quarter ended March 31, 2016.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â First Quarter 2016 Highlights

Revenue of $67.8 million;Reported gross profit of $16.8 million, or 25% of net revenue;Completed sale of Sagent (China) Pharmaceuticals (SCP) resulting in $4.3 million net loss, while also reducing cost structure by approximately $10 million per year and strengthening development and supply relationship with long-term strategic partnerAdjusted... More

Sagent Pharmaceuticals (SGNT) Misses Q1 EPS by 16c

Sagent Pharmaceuticals Reports First Quarter 2016 Financial Results

Free News Feed